IGC Pharma (IGC) Cost of Revenue (2010 - 2025)
IGC Pharma (IGC) posted quarterly Cost of Revenue of $92000.0 for Q3 2025, down 57.01% year-over-year from $214000.0 in Q3 2024, and down 47.13% quarter-over-quarter from $174000.0 in Q2 2025.
IGC Pharma (IGC) Cost of Revenue (2010 - 2025) Analysis & Trends
IGC Pharma (IGC) has reported Cost of Revenue for 16 consecutive years, with $92000.0 the latest figure, recorded in Q3 2025.
- In Q3 2025, Cost of Revenue fell 57.01% year-over-year to $92000.0; the TTM figure through Sep 2025 stood at $595000.0 (up 14.86% YoY), while the FY2026 annual figure was $262000.0, down 59.82% from the prior year.
- Cost of Revenue retreated to $92000.0 in Q3 2025 per IGC's latest filing, from $174000.0 in the prior quarter.
- Across five years, Cost of Revenue topped out at $300000.0 in Q2 2023 and bottomed at $18000.0 in Q3 2021.
- Historically, Cost of Revenue has averaged $118789.5 across 5 years, with a median of $103000.0 in 2023.
- Annual changes were most pronounced in 2021 — Cost of Revenue plunged 90.52% — and 2023, when it surged 328.57%.
- IGC Pharma's Cost of Revenue stood at $80000.0 in 2021, then jumped by 187.5% to $230000.0 in 2022, then plunged by 69.13% to $71000.0 in 2023, then soared by 115.49% to $153000.0 in 2024, then tumbled by 39.87% to $92000.0 in 2025.
- Business Quant data shows IGC's Cost of Revenue at $92000.0 in Q3 2025, $174000.0 in Q2 2025, and $176000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 489.20 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 360.70 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 145.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 93.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 174.53 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 298.26 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 67.21 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 387.98 Mn |
| 10 | IGC Pharma | 27.20 Mn | 26.94 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 92,000.00 |
| Sep 30, 2025 | 92,000.00 |
| Jun 30, 2025 | 174,000.00 |
| Jun 30, 2025 | 174,000.00 |
| Mar 31, 2025 | 176,000.00 |
| Mar 31, 2025 | 176,000.00 |
| Dec 31, 2024 | 153,000.00 |
| Dec 31, 2024 | 153,000.00 |
| Sep 30, 2024 | 214,000.00 |
| Sep 30, 2024 | 214,000.00 |
| Jun 30, 2024 | 109,000.00 |
| Jun 30, 2024 | 109,000.00 |
| Mar 31, 2024 | 124,000.00 |
| Mar 31, 2024 | 124,000.00 |
| Dec 31, 2023 | 71,000.00 |
| Dec 31, 2023 | 71,000.00 |
| Sep 30, 2023 | 117,000.00 |
| Sep 30, 2023 | 117,000.00 |
| Jun 30, 2023 | 300,000.00 |
| Jun 30, 2023 | 300,000.00 |